Metraipolis › archive › dc_fcb98577aae8
Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy — Europe PMC PMID:39859189
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/39859189
- DOI
- 10.3390/ijms26020474
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T20:28:35.741Z
- SHA-256 of the archived text
bdc604a3d569aa777b84f98f7c8cd2e96abcddba2c73d55550065241a870806c- Stable URL of this page
https://metraipolis.com/documento/dc_fcb98577aae8
How to cite
Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy — Europe PMC PMID:39859189 — Europe PMC (en), https://europepmc.org/article/MED/39859189 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fcb98577aae8 (Metraipolis archive dc_fcb98577aae8, sha256 bdc604a3d569aa777b84f98f7c8cd2e96abcddba2c73d55550065241a870806c)
BibTeX
@misc{dcfcb98577aae8,
title = {Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy — Europe PMC PMID:39859189},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/39859189},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fcb98577aae8; sha256 bdc604a3d569aa777b84f98f7c8cd2e96abcddba2c73d55550065241a870806c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39859189. Agents can read the archived copy with the MCP tool read_document.